Related Experiment Video
Updated: Jul 5, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
Alteration of gene expression during progression of hypertension-induced cardiac dysfunction in rats
Tomoyoshi Koyanagi1, Lily Y Wong, Koichi Inagaki
1Dept. of Chemical and Systems Biology, Stanford Univ. School of Medicine, Stanford, CA 94305-5174, USA.
Insights
This study identifies distinct molecular markers differentiating compensatory cardiac hypertrophy from decompensated cardiac dysfunction in salt-induced hypertension models. These findings aid in understanding disease progression and developing targeted therapies.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Hypertension Research
Background:
- High-salt diet-induced hypertension in Dahl rats causes cardiac hypertrophy and dysfunction.
- The molecular differences between compensatory hypertrophy and decompensated cardiac dysfunction remain unclear.
Purpose of the Study:
- To identify molecular hallmarks distinguishing compensatory cardiac hypertrophy from decompensated cardiac dysfunction.
- To compare gene expression profiles at different stages of hypertension-induced heart disease.
Main Methods:
- Quantitative real-time PCR was used to measure mRNA levels of 93 selected genes in rat cardiac tissue.
- Gene expression was analyzed in compensatory hypertrophy (11 wk), cardiac dysfunction (17 wk), and control groups.
- Principal component analysis was employed to segregate animals based on disease stage.
Main Results:
- During compensatory hypertrophy, atrial natriuretic peptide (ANP) and brain natriuretic peptide increased, while SOD2 and SERCA2a decreased.
- In cardiac dysfunction, inducible nitric oxide synthase (NOS) and angiotensin I-converting enzyme (ACE) increased.
- Gene expression patterns significantly differed between compensatory hypertrophy and cardiac dysfunction phases, with 22 genes showing altered expression.
Conclusions:
- Distinct molecular signatures characterize compensatory hypertrophy and decompensated cardiac dysfunction in this hypertension model.
- Identified gene expression changes provide potential molecular markers for disease staging.
- Principal component analysis successfully differentiated disease stages, validating the identified molecular markers.
Abstract:
Hypertension induced by high-salt diet in Dahl salt-sensitive rats leads to compensatory cardiac hypertrophy by approximately 11 wk, cardiac dysfunction at approximately 17 wk, and death from cardiac dysfunction at approximately 21 wk. It is unclear what molecular hallmarks distinguish the compensatory hypertrophy from the decompensated cardiac dysfunction phase. Here we compared the gene expression in rat cardiac tissue from the compensatory hypertrophic phase (11 wk, n = 6) with the cardiac dysfunction phase (17 wk, n = 6) and with age-matched normotensive controls. Messenger RNA levels of 93 genes, selected based on predicted association with cardiac dysfunction, were measured by quantitative real-time PCR. In the hypertrophic phase, the expression of three genes, atrial natriuretic peptide (ANP; P = 0.0089), brain natriuretic peptide (P = 0.0012), and endothelin-1 precursor (P = 0.028), significantly increased, whereas there was decreased expression of 24 other genes including SOD2 (P = 0.0148), sarco(endo)plasmic reticulum Ca(2+)-ATPase 2a (P = 0.0002), and ryanodine receptor 2 (P = 0.0319). In the subsequent heart cardiac dysfunction phase, the expression of an additional 20 genes including inducible nitric oxide synthase (NOS; P = 0.0135), angiotensin I-converting enzyme (P = 0.0082), and IL-1beta (P < 0.0001) increased, whereas the expression of seven genes decreased compared with those of age-matched controls. Furthermore, the expression of 22 genes, including prepro-endothelin-1, ANP, angiotensin I-converting enzyme, beta(1)-adrenergic receptor, SOD2, and endothelial NOS, significantly changed in the cardiac dysfunction phase compared with the compensatory hypertrophic phase. Finally, principal component analysis successfully segregated animals with decompensatory cardiac dysfunction from controls, as well as from animals at the compensated hypertrophy phase, suggesting that we have identified molecular markers for each stage of the disease.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Hypertension II: Pathophysiology
Pathophysiology of Heart Failure

